SLC5A2 and osteosarcoma: To explore the specific mechanism underlying the regulation of osteosarcoma progression by the SGLT2 inhibitor (canagliflozin, 1 uM), we performed RNA sequence analysis and determined 664 downregulated differentially expressed genes and 305 upregulated differentially expressed genes in SGLT2 inhibitor-treated osteosarcoma cells (Fig. 3a, b).